The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).
David W. Ollila
No relevant relationships to disclose
Donald A. Berry
No relevant relationships to disclose
Constance Cirrincione
No relevant relationships to disclose
Lisa A. Carey
No relevant relationships to disclose
Keith D. Amos
No relevant relationships to disclose
Norah Lynn Henry
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Clifford Hudis
Research Funding - Merck
Other Remuneration - Estee Lauder Company (I)
Mehra Golshan
No relevant relationships to disclose